Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • Texas
  • Houston


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 02:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Brief Religious Alcohol Intervention
    NCT04075773
    Condition:   Heavy Drinking
    Intervention:   Behavioral: Expressive Writing
    Sponsor:   University of Houston
    Recruiting
  • Efficacy And Tolerability Of Sub-Anesthetic Ketamine In Postpartum Depression
    NCT04011592
    Condition:   Post Partum Depression
    Interventions:   Drug: Ketamine 0.5 mg/kg;   Drug: Ketamine 0.2 mg/kg
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting
  • Quit4Health Intervention in Supporting Smoking Cessation and Preventing Smoking Initiation in Young Adults
    NCT04009590
    Conditions:   Cigarette Smoking;   Current Smoker
    Interventions:   Other: Educational Intervention;   Other: Questionnaire Administration;   Behavioral: Smoking Cessation Intervention
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   National Institute on Drug Abuse (NIDA)
    Recruiting
  • Fetal Endotracheal Occlusion (FETO) in the Resolution of Pulmonary Hypertension in Fetuses With Severe CDH
    NCT03980717
    Condition:   Congenital Diaphragmatic Hernia
    Intervention:   Device: Goldbal Detachable Balloon and delivery microcatheter
    Sponsors:   Michael Belfort;   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting
  • Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida
    NCT03961360
    Conditions:   Pre-Eclampsia;   Hypertension in Pregnancy;   Obesity
    Interventions:   Drug: Aspirin 81 mg;   Drug: Aspirin 162 mg
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting
  • Brief Personalized Feedback Intervention for Hazardous Drinking in an HIV Clinic
    NCT03935945
    Condition:   Alcohol Consumption
    Intervention:   Behavioral: Personalized Feedback Intervention
    Sponsors:   University of Houston;   Baylor College of Medicine
    Recruiting
  • The Effect of a Scleral Lens on the Anterior Chamber Depth and Minimum Rim Width
    NCT03926975
    Condition:   Ocular Hypertension
    Interventions:   Device: Scleral Lens;   Other: No lens
    Sponsor:   University of Houston
    Recruiting
  • Serial Third Trimester Abdominal Circumference and Amniotic Fluid Measurements Versus Routine Care
    NCT03857659
    Conditions:   Fetal Growth Abnormality;   Amniotic Fluid; Disorder
    Interventions:   Diagnostic Test: Point-of-care ultrasound (POC-US);   Diagnostic Test: Routine antenatal care;   Diagnostic Test: Formal ultrasound
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting
  • Electrophysiological Biomarkers of AV-101
    NCT03583554
    Condition:   Healthy
    Interventions:   Drug: AV-101 720 mg;   Drug: Placebo;   Drug: AV-101 1440 mg
    Sponsors:   Marijn Lijffijt, PhD;   Michael Debakey Veterans Affairs Medical Center;   VistaGen Therapeutics, Inc.
    Recruiting
  • Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse
    NCT03539887
    Conditions:   Suicidal Ideation;   Depression;   Alcohol Abuse
    Interventions:   Drug: Intranasal ketamine;   Drug: Placebo
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting
  • Project PRIDE (Promoting Resilience In Discriminatory Environments)
    NCT03528135
    Conditions:   Human Immunodeficiency Virus;   Sexually Transmitted Infections;   Anxiety;   Depression;   Substance Use Disorders
    Intervention:   Behavioral: Project PRIDE
    Sponsors:   University of Houston;   National Institute on Drug Abuse (NIDA)
    Recruiting
  • Neurofeedback for PTSD
    NCT03482466
    Condition:   Post-traumatic Stress Disorder
    Intervention:   Behavioral: Neurofeedback
    Sponsors:   VA Office of Research and Development;   Baylor College of Medicine
    Recruiting
  • Fetal Endotracheal Occlusion (FETO) in Severe and Extremely Severe Congenital Diaphragmatic Hernia
    NCT00881660
    Condition:   Congenital Diaphragmatic Hernia
    Intervention:   Device: Goldballoon Detachable Balloon and delivery microcatheter
    Sponsors:   Michael Belfort;   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting
  • Trial to Evaluate Safety, Tolerability, Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis
    NCT04093895
    Condition:   Periodontitis
    Intervention:   Drug: PerioSept(r)
    Sponsor:   Geistlich Pharma AG
    Recruiting
  • Strength on Wheels: A Meal Delivery and Exercise Intervention for Homebound Older Adults
    NCT04087343
    Condition:   Frailty
    Interventions:   Behavioral: Meals plus exercise;   Behavioral: Meals only
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting
  • Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer
    NCT04087057
    Condition:   Invasive Breast Carcinoma
    Interventions:   Other: Interview;   Other: Medical Chart Review;   Behavioral: Questionnaire
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Azacitidine and Venetoclax in Treating Patients With High Risk Acute Myeloid Leukemia in Remission
    NCT04062266
    Conditions:   Acute Myeloid Leukemia in Remission;   FLT3 Gene Mutation;   Hematologic and Lymphocytic Disorder;   High Risk Acute Myeloid Leukemia;   Minimal Residual Disease Persistence;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Genentech, Inc.
    Recruiting
  • Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
    NCT04054167
    Conditions:   Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma
    Intervention:   Drug: Low Dose Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • An Investigational Device (Millar Mikro-Tip Catheter) and Imaging Scan (Shear Wave Elastography) in Measuring Tumor Pressure and Stiffness in Patients With Solid Tumors Undergoing Ultrasound-Guided Biopsy
    NCT04054154
    Condition:   Solid Neoplasm
    Interventions:   Device: Shear Wave Elastography;   Procedure: Tumor Interstitial Fluid Pressure Measurement
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Financial Distress in Advanced Cancer Patients
    NCT04053517
    Conditions:   Advanced Malignant Neoplasm;   Locally Advanced Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Recurrent Malignant Neoplasm;   Refractory Malignant Neoplasm
    Interventions:   Other: Medical Chart Review;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury
    NCT04051957
    Conditions:   Kidney Injury;   Proteinuria;   Hypertension
    Interventions:   Drug: Isosorbide Mononitrate;   Drug: Placebo oral tablet
    Sponsors:   The University of Texas Health Science Center, Houston;   National Kidney Foundation
    Recruiting
  • Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
    NCT04047797
    Conditions:   Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma
    Interventions:   Drug: Ixazomib;   Drug: Ixazomib Citrate;   Biological: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Sleep, the Never-ending Quest of College Students
    NCT04035213
    Conditions:   Sleep;   Sleep Disturbance;   Sleep Hygiene
    Intervention:   Behavioral: Behavior of Sleep Course
    Sponsor:   University of Houston
    Recruiting
  • Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
    NCT04030455
    Conditions:   Laryngeal Squamous Cell Carcinoma;   Stage II Laryngeal Cancer AJCC v8;   Stage III Laryngeal Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Docetaxel;   Biological: Pembrolizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Effects of Computer-Assisted Cognitive Rehabilitation Programs With Breast Cancer Survivors
    NCT04027400
    Conditions:   Cognitive Impairment;   Breast Cancer
    Intervention:   Behavioral: computer-assisted rehabilitation
    Sponsor:   Texas Woman's University
    Recruiting
  • PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
    NCT04022785
    Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm
    Interventions:   Drug: Azacitidine;   Drug: BRD4 Inhibitor PLX51107
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer
    NCT04022772
    Condition:   Breast Carcinoma
    Interventions:   Other: Best Practice;   Other: Medical Chart Review;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Supportive Care
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Genentech, Inc.
    Recruiting
  • An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer
    NCT04022746
    Conditions:   Advanced Adult Hepatocellular Carcinoma;   Stage III Hepatocellular Carcinoma AJCC v8;   Stage IIIA Hepatocellular Carcinoma AJCC v8;   Stage IIIB Hepatocellular Carcinoma AJCC v8;   Stage IV Hepatocellular Carcinoma AJCC v8;   Stage IVA Hepatocellular Carcinoma AJCC v8;   Stage IVB Hepatocellular Carcinoma AJCC v8
    Interventions:   Procedure: Magnetic Resonance Elastography;   Procedure: Magnetic Resonance Imaging
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
    NCT04021043
    Conditions:   Advanced Malignant Solid Neoplasm;   Metastatic Carcinoma in the Liver;   Metastatic Carcinoma in the Lung;   Metastatic Malignant Neoplasm in the Thoracic Cavity;   Metastatic Malignant Solid Neoplasm
    Interventions:   Drug: Anti-GITR Agonistic Monoclonal Antibody BMS-986156;   Biological: Ipilimumab;   Biological: Nivolumab;   Radiation: Stereotactic Body Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Caring for Caregivers With Mind-body Exercise
    NCT04019301
    Conditions:   Caregiver Distress;   Physical Function;   Quality of Life
    Interventions:   Other: Baduanjin Qigong, Community-based;   Other: Baduanjin Qigong, Internet-based
    Sponsors:   Texas Woman's University;   Brigham and Women's Hospital
    Recruiting
  • Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
    NCT04017650
    Conditions:   BRAF NP_004324.2:p.V600E;   Metastatic Colon Adenocarcinoma;   Metastatic Microsatellite Stable Colorectal Carcinoma;   Metastatic Rectal Adenocarcinoma;   Progressive Disease;   Recurrent Colorectal Carcinoma;   Stage III Colorectal Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8;   Unresectable Colon Adenocarcinoma;   Unresectable Rectal Adenocarcinoma
    Interventions:   Biological: Cetuximab;   Drug: Encorafenib;   Biological: Nivolumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS
    NCT04017546
    Conditions:   AML;   MDS
    Interventions:   Drug: CYC065;   Drug: Venetoclax
    Sponsors:   Cyclacel Pharmaceuticals, Inc.;   M.D. Anderson Cancer Center
    Recruiting
  • Self Cranial Electrical Stimulation (CES) for Pain in Older Adults With Knee Osteoarthritis (Self CES for Knee Pain)
    NCT04016259
    Condition:   Osteo Arthritis Knee
    Interventions:   Device: Cranial Electrical Stimulation (CES);   Device: Sham-CES
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting
  • Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer
    NCT04013542
    Conditions:   ALK Gene Rearrangement;   EGFR Gene Mutation;   Locally Advanced Lung Non-Small Cell Carcinoma;   Lung Non-Small Cell Carcinoma;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Unresectable Lung Non-Small Cell Carcinoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab;   Radiation: Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
    NCT04013334
    Condition:   Malignant Pleural Mesothelioma
    Interventions:   Drug: MTG201;   Drug: Nivolumab Injection [Opdivo]
    Sponsors:   Momotaro-Gene Inc.;   Baylor College of Medicine;   Synteract, Inc.
    Recruiting
  • Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
    NCT04003038
    Conditions:   Body Mass Index Greater Than or Equal to 30;   Malignant Breast Neoplasm;   Mammoplasty Patient;   Obesity
    Interventions:   Procedure: Negative Pressure Wound Therapy;   Procedure: Wound Care Management
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization
    NCT03990623
    Condition:   Liver and Intrahepatic Bile Duct Carcinoma
    Interventions:   Radiation: Computed Tomography Perfusion Imaging;   Procedure: Liver Biopsy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction
    NCT03990610
    Conditions:   Breast Carcinoma;   Mammoplasty Patient
    Interventions:   Procedure: Mammoplasty;   Procedure: Vascularized Lymph Node Transfer
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
    NCT03990571
    Conditions:   Metastatic Adenoid Cystic Carcinoma;   Progressive Disease;   Recurrent Adenoid Cystic Carcinoma
    Interventions:   Drug: Avelumab;   Drug: Axitinib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Survey of Cancer Patients' Perceptions of Difficulties Encountered When Filling Opioid Prescriptions
    NCT03989128
    Conditions:   Malignant Neoplasm;   Pain
    Interventions:   Other: Medical Chart Review;   Other: Survey Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
    NCT03987386
    Conditions:   Stage I Prostate Cancer AJCC v8;   Stage II Prostate Cancer AJCC v8;   Stage IIA Prostate Cancer AJCC v8;   Stage IIB Prostate Cancer AJCC v8;   Stage IIC Prostate Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage IIIB Prostate Cancer AJCC v8;   Stage IIIC Prostate Cancer AJCC v8
    Interventions:   Radiation: Hypofractionated Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • New Magnetic Resonance Imaging and Spectroscopy Software in the Improvement of Image Quality
    NCT03980535
    Conditions:   Health Status Unknown;   Healthy Subject
    Interventions:   Procedure: Magnetic Resonance Imaging;   Procedure: Magnetic Resonance Spectroscopic Imaging
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • SuperNO2VA™ and General Anesthesia Postoperative Care
    NCT03969615
    Conditions:   Hypoxemia;   Acute Respiratory Failure
    Interventions:   Device: SuperNO2VA nasal positive airway pressure devic;   Device: Supplemental oxygen
    Sponsors:   Vyaire Medical;   M.D. Anderson Cancer Center
    Recruiting
  • Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
    NCT03968406
    Conditions:   Recurrent Cervical Carcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Vaginal Carcinoma;   Stage IV Cervical Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Stage IV Uterine Corpus Cancer AJCC v8;   Stage IV Vaginal Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Fallopian Tube Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Primary Peritoneal Cancer AJCC v8;   Stage IVA Uterine Corpus Cancer AJCC v8;   Stage IVA Vaginal Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Fallopian Tube Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Primary Peritoneal Cancer AJCC v8;   Stage IVB Uterine Corpus Cancer AJCC v8;   Stage IVB Vaginal Cancer AJCC v8
    Interventions:   Procedure: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Talazoparib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Time From Onset of Fever to Administration of Antibiotics in Neutropenic Fever Patients
    NCT03968328
    Conditions:   Febrile Neutropenia;   Fever
    Interventions:   Other: Interview;   Other: Survey Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer
    NCT03965481
    Conditions:   Malignant Ovarian Neoplasm;   Ovarian Carcinoma
    Interventions:   Radiation: Dynamic Enhanced CT;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Resting-State Functional MRI in Glioma Patients Before and After Surgery
    NCT03964909
    Conditions:   Brain Mass;   Glioma
    Interventions:   Procedure: Functional Magnetic Resonance Imaging;   Procedure: Magnetic Resonance Imaging;   Procedure: Resting State Functional Connectivity Magnetic Resonance Imaging
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds
    NCT03960463
    Conditions:   Surgical Wound;   Diabetes;   Amputation Wound;   Incision Wound;   Peripheral Arterial Disease;   Breast Cancer;   Diabetic Foot
    Intervention:   Device: Transcu O2®
    Sponsors:   Baylor College of Medicine;   Electrochemical Oxygen Concepts, Inc.
    Recruiting
  • Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas
    NCT03953131
    Condition:   Meningioma
    Interventions:   Procedure: Computed Tomography;   Radiation: Gallium Ga 68-DOTATATE;   Procedure: Positron Emission Tomography
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Dietary Intervention in Patients With a History of Melanoma
    NCT03950635
    Conditions:   Melanoma;   No Evidence of Disease
    Interventions:   Dietary Supplement: Dietary Intervention;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
    NCT03950609
    Conditions:   Advanced Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Multiple Endocrine Neoplasia Type 1;   Neuroendocrine Neoplasm;   Unresectable Carcinoid Tumor
    Interventions:   Drug: Everolimus;   Drug: Lenvatinib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-III Non-small Cell Lung Cancer Undergoing Radiotherapy and Their Caregivers
    NCT03948100
    Conditions:   Caregiver;   Lung Non-Small Cell Carcinoma;   Stage I Lung Cancer AJCC v8;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8
    Interventions:   Other: Educational Intervention;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Yoga
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
    NCT03946878
    Conditions:   Blastoid Variant Mantle Cell Lymphoma;   CCND1 Protein Overexpression;   CD20 Positive;   CD5 Positive;   FCER2 Negative;   Pleomorphic Variant Mantle Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   t(11;14)(q13;q32)
    Interventions:   Drug: Acalabrutinib;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Postmenopausal Pessary Users: Estrogen Versus Trimosan
    NCT03943823
    Conditions:   Vaginosis;   Vaginosis, Bacterial;   Vaginal Discharge
    Interventions:   Drug: Estrogen vaginal cream;   Drug: Trimo-San vaginal gel
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting
  • Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
    NCT03943173
    Conditions:   BRCA-Mutated Ovarian Carcinoma;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Stage III Fallopian Tube Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Primary Peritoneal Cancer AJCC v8;   Stage IIIA Fallopian Tube Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Primary Peritoneal Cancer AJCC v8;   Stage IIIA1 Fallopian Tube Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Fallopian Tube Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Fallopian Tube Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Primary Peritoneal Cancer AJCC v8;   Stage IIIC Fallopian Tube Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Primary Peritoneal Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Stage IVA Fallopian Tube Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Primary Peritoneal Cancer AJCC v8;   Stage IVB Fallopian Tube Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Primary Peritoneal Cancer AJCC v8
    Interventions:   Drug: Chemotherapy;   Drug: Olaparib;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Trial of DFP-14927 in Advanced Solid Tumors
    NCT03943004
    Conditions:   Solid Tumor;   Cancer
    Intervention:   Drug: DFP-14927
    Sponsor:   Delta-Fly Pharma, Inc.
    Recruiting
  • Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer
    NCT03941756
    Conditions:   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Inflammatory Breast Carcinoma;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8
    Interventions:   Drug: Indocyanine Green;   Procedure: Lymphangiography;   Procedure: Lymphovenous Bypass
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer
    NCT03927885
    Conditions:   Advanced Malignant Solid Neoplasm;   Cancer Fatigue;   Metastatic Malignant Solid Neoplasm;   Pain;   Recurrent Malignant Solid Neoplasm
    Interventions:   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Waiting List
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • F18 Fluciclovine PET/CT in Assessing Tumor Volume and Radiation Therapy Response in Patients With Glioblastoma Undergoing Surgery
    NCT03926507
    Condition:   Glioblastoma
    Interventions:   Procedure: Computed Tomography;   Other: Fluciclovine F18;   Procedure: Positron Emission Tomography
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Personalized Feedback for Distress Intolerant Smokers
    NCT03918031
    Conditions:   Anxiety Disorders;   Depression;   Psychological Distress;   Tobacco Dependence;   Smoking, Tobacco;   Smoking, Cigarette
    Interventions:   Behavioral: PFI for Smoking & Distress Tolerance;   Behavioral: PFI for Smoking Only
    Sponsors:   University of Houston;   National Institute on Drug Abuse (NIDA)
    Recruiting
  • Computer-Delivered Intervention for Obese Sedentary Individuals With Elevated Anxiety Sensitivity
    NCT03917901
    Conditions:   Obesity;   Anxiety Sensitivity;   Eating;   Physical Activity
    Interventions:   Other: Anxiety Sensitivity Training;   Other: Health Control
    Sponsor:   University of Houston
    Recruiting
  • Computer-Delivered PFI for Anxiety Sensitivity/Alcohol Intervention for Hazardous Drinkers With Elevated Anxiety Sensitivity
    NCT03917875
    Conditions:   Alcohol Drinking;   Anxiety;   Coping Behavior
    Intervention:   Behavioral: Personalized feedback intervention
    Sponsor:   University of Houston
    Recruiting
  • Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    NCT03909334
    Conditions:   Non Small Cell Lung Cancer;   EGFR Gene Mutation;   Advanced Cancer;   Metastatic Cancer
    Interventions:   Drug: Osimertinib;   Drug: Ramucirumab
    Sponsors:   Xiuning Le;   M.D. Anderson Cancer Center;   Eli Lilly and Company
    Recruiting
  • Peer-led Group Intervention for Coping With Disaster
    NCT03907995
    Conditions:   Anxiety Disorder;   PTSD;   Depressive Symptoms;   Anger;   Depressive Disorder
    Intervention:   Behavioral: Cognitive Behavioral Therapy
    Sponsors:   Baylor College of Medicine;   American National Red Cross
    Recruiting
  • CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
    NCT03896269
    Conditions:   Blasts 10-19 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   High Risk Chronic Myelomonocytic Leukemia;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory Chronic Myelomonocytic Leukemia;   Refractory High Risk Myelodysplastic Syndrome
    Intervention:   Drug: Liposome-encapsulated Daunorubicin-Cytarabine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Early Metabolic Resuscitation for Septic Shock
    NCT03895853
    Conditions:   Multiple Organ Failure;   Septic Shock;   Severe Sepsis
    Interventions:   Other: Best Practice;   Dietary Supplement: early metabolic resuscitation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
    NCT03894540
    Condition:   Solid Tumor
    Interventions:   Drug: IPN60090;   Drug: pembrolizumab;   Drug: paclitaxel;   Drug: IPN60090 single administration
    Sponsor:   Ipsen
    Recruiting
  • Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers
    NCT03892993
    Conditions:   Cancer Survivor;   Caregiver;   Family Member;   Health Care Provider;   Thyroid Gland Medullary Carcinoma
    Interventions:   Other: Decision Aid;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
    NCT03887936
    Conditions:   Type 2 Diabetes Mellitus;   Hypogonadism
    Interventions:   Drug: Testosterone gel 1.62%;   Drug: Placebo
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor
    NCT03884972
    Conditions:   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma
    Interventions:   Drug: Trabectedin;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
    NCT03873818
    Conditions:   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Metastatic Malignant Neoplasm in the Brain;   Metastatic Melanoma;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Biological: Ipilimumab;   Biological: Pembrolizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
    NCT03872388
    Conditions:   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Estrogen Receptor Negative;   HER2/Neu Negative;   Inflammatory Breast Carcinoma;   Progesterone Receptor Negative;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Atorvastatin;   Drug: Capecitabine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease
    NCT03868020
    Conditions:   Metastatic Head and Neck Squamous Cell Carcinoma;   Metastatic Squamous Cell Carcinoma in Cervical Lymph Node
    Interventions:   Procedure: Computed Tomography;   Radiation: Fluciclovine F18;   Procedure: Positron Emission Tomography
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
    NCT03865082
    Condition:   Solid Tumor
    Interventions:   Drug: Tilsotolimod;   Drug: Nivolumab;   Drug: Ipilimumab
    Sponsors:   Idera Pharmaceuticals, Inc.;   Bristol-Myers Squibb
    Recruiting
  • Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
    NCT03862157
    Conditions:   Acute Myeloid Leukemia;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Chronic Eosinophilic Leukemia, Not Otherwise Specified;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Dysplasia;   Essential Thrombocythemia;   FGFR1 Gene Rearrangement;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Myeloid Neoplasm;   Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm, Unclassifiable;   Overt Primary Myelofibrosis;   PDGFRA Gene Rearrangement;   PDGFRB Gene Rearrangement;   Polycythemia Vera;   Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase;   Prefibrotic/Early Primary Myelofibrosis
    Interventions:   Drug: Azacitidine;   Drug: Pevonedistat;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease
    NCT03854019
    Conditions:   Huntington Disease;   Irritability
    Interventions:   Drug: Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg);   Drug: Placebo
    Sponsors:   The University of Texas Health Science Center, Houston;   Cures Within Reach
    Recruiting
  • Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
    NCT03830151
    Condition:   Primary Brain Neoplasm
    Interventions:   Drug: Hyperpolarized Carbon C 13 Pyruvate;   Procedure: Magnetic Resonance Spectroscopic Imaging
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease
    NCT03827564
    Condition:   Dry Eye Syndromes
    Intervention:   Device: Intranasal Tear Neurostimulator (ITN) [TrueTear®]
    Sponsor:   Allergan
    Recruiting
  • Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
    NCT03821792
    Conditions:   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma;   Prostate Carcinoma Metastatic in the Bone;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
    Interventions:   Drug: Abiraterone Acetate;   Drug: Apalutamide;   Drug: Prednisone
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • AVAZZIA Electrical Stimulation
    NCT03821675
    Conditions:   Diabetes;   Diabetic Foot Ulcer;   Peripheral Neuropathy;   Peripheral Arterial Disease
    Interventions:   Device: Electrical Stimulation;   Device: Electrical Stimulation - Sham
    Sponsors:   Baylor College of Medicine;   Avazzia, Inc;   Brian Lepow, DPM
    Recruiting
  • Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk
    NCT03819985
    Conditions:   Resectable Soft Tissue Sarcoma;   Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8;   Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8;   Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8;   Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8;   Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8;   Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8;   Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
    Interventions:   Radiation: Hypofractionated Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Pain Control With Pre-operative Cryoneurolysis Following TKA
    NCT03818022
    Condition:   Osteo Arthritis Knee
    Intervention:   Procedure: Cryoneurolysis (Iovera)
    Sponsor:   Fondren Orthopedic Group L.L.P.
    Recruiting
  • Transdiagnostic CBT for Anxiety
    NCT03810456
    Condition:   Anxiety Disorders
    Interventions:   Behavioral: Intensive Cognitive Behavior Therapy (iCBT);   Behavioral: Standard Cognitive Behavior Therapy (sCBT)
    Sponsor:   VA Office of Research and Development
    Recruiting
  • Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
    NCT03808610
    Conditions:   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent T Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia;   Refractory T Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Nelarabine;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
    NCT03799445
    Conditions:   Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma;   Oropharyngeal Basaloid Carcinoma;   Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Posterior Tongue Squamous Cell Carcinoma;   Soft Palate Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Tonsillar Squamous Cell Carcinoma
    Interventions:   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors
    NCT03784677
    Conditions:   Advanced Malignant Solid Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Ovarian Carcinoma;   Refractory Pancreatic Carcinoma;   Stage II Pancreatic Cancer AJCC v8;   Stage IIA Pancreatic Cancer AJCC v8;   Stage IIB Pancreatic Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Prostate Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Prostate Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
    Intervention:   Drug: TRPV6 Calcium Channel Inhibitor SOR-C13
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Atezolizumab, Oxaliplatin, and Fluorouracil in Treating Patients With Esophageal or Gastroesophageal Cancer
    NCT03784326
    Conditions:   Clinical Stage II Esophageal Adenocarcinoma AJCC v8;   Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage III Esophageal Adenocarcinoma AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage II Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage III Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
    Interventions:   Drug: Atezolizumab;   Procedure: Conventional Surgery;   Drug: Fluorouracil;   Drug: Oxaliplatin
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
    NCT03776487
    Conditions:   Clinical Stage 0 Gastric Cancer AJCC v8;   Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage I Gastric Cancer AJCC v8;   Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IIB Gastric Cancer AJCC v8;   Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastric Cancer AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Gastric Adenocarcinoma;   Localized Gastric Carcinoma;   Localized Gastroesophageal Junction Adenocarcinoma;   Pathologic Stage 0 Gastric Cancer AJCC v8;   Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage I Gastric Cancer AJCC v8;   Pathologic Stage IA Gastric Cancer AJCC v8;   Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IB Gastric Cancer AJCC v8;   Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIA Gastric Cancer AJCC v8;   Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIB Gastric Cancer AJCC v8;   Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastric Cancer AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
    Interventions:   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Ipilimumab;   Biological: Nivolumab;   Drug: Oxaliplatin;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Participants With Estrogen Receptor Positive, HER2 Negative Breast Cancer
    NCT03774472
    Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   MKI67 Positive;   Postmenopausal;   Prognostic Stage I Breast Cancer AJCC v8;   Prognostic Stage IA Breast Cancer AJCC v8;   Prognostic Stage IB Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8
    Interventions:   Drug: Hydroxychloroquine;   Drug: Letrozole;   Drug: Palbociclib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)
    NCT03773393
    Condition:   Bone Marrow Disease
    Intervention:   Biological: CK0801
    Sponsor:   Cellenkos, Inc.
    Recruiting
  • Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer
    NCT03772834
    Condition:   Prostate Carcinoma
    Interventions:   Behavioral: Exercise Intervention;   Drug: Methylphenidate;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Stretching
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
    NCT03770416
    Conditions:   Central Nervous System B-Cell Non-Hodgkin Lymphoma;   Recurrent Central Nervous System Lymphoma;   Refractory Central Nervous System Lymphoma
    Interventions:   Drug: Ibrutinib;   Biological: Nivolumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
    NCT03763162
    Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Drug: Bortezomib;   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Ixazomib;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   Takeda
    Recruiting
  • TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors
    NCT03756818
    Conditions:   Advanced Malignant Solid Neoplasm;   KRAS Gene Mutation;   Ovarian Carcinoma;   Refractory Malignant Solid Neoplasm;   Refractory Ovarian Carcinoma
    Interventions:   Drug: Paclitaxel;   Other: Pharmacokinetic Study;   Drug: Spleen Tyrosine Kinase Inhibitor TAK-659
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related Fatigue
    NCT03747757
    Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Cancer Fatigue;   Lymphoma;   Secondary Acute Myeloid Leukemia
    Interventions:   Behavioral: Cognitive Behavior Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery
    NCT03745794
    Condition:   Pancreatic Carcinoma
    Interventions:   Other: Best Practice;   Drug: Quadratus Lumborum Block;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer
    NCT03744793
    Conditions:   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation;   Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation;   Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Urothelial Carcinoma;   MTAP Negative
    Interventions:   Drug: Avelumab;   Drug: Pemetrexed
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
    NCT03741673
    Conditions:   Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
    Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Radiosurgery
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
    NCT03735875
    Conditions:   Acute Myeloid Leukemia With FLT3/ITD Mutation;   FLT3 Gene Mutation;   FLT3 Internal Tandem Duplication;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Leukemia
    Interventions:   Drug: Quizartinib;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
    NCT03725436
    Conditions:   Advanced Malignant Solid Neoplasm;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Metastatic Malignant Solid Neoplasm;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Recurrent Breast Carcinoma;   TP53 wt Allele;   Unresectable Malignant Solid Neoplasm
    Interventions:   Drug: MDM2/MDMX Inhibitor ALRN-6924;   Drug: Paclitaxel
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Clinical and Histological Outcomes of Allogenic Amnion Chorion Membrane in the Healing of Free Gingival Graft Donor Site
    NCT03713073
    Condition:   Palatal Wound
    Interventions:   Device: Allogenic amnion chorion membrane;   Device: Collagen dressing
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting
  • Single Center Post Approval Proximal Humerus Fixation With the Conventus Cage PH™ Device
    NCT03711591
    Condition:   Proximal Humeral Fracture
    Intervention:   Device: Conventus Cage PH device
    Sponsor:   Conventus Orthopaedics, Inc.
    Recruiting
  • Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
    NCT03710772
    Conditions:   CD20 Positive;   Mantle Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Ibrutinib;   Drug: Methotrexate;   Biological: Rituximab;   Drug: Venetoclax;   Drug: Vincristine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer
    NCT03707938
    Conditions:   Advanced Lung Carcinoma;   ALK Gene Rearrangement;   Lung Non-Small Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Brigatinib;   Procedure: Local Consolidation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Bronchoscopic Laser Ablation of Peripheral Lung Tumors
    NCT03707925
    Conditions:   Lung Carcinoid Tumor;   Lung Non-Small Cell Carcinoma;   Metastatic Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Procedure: Cone-Beam Computed Tomography;   Procedure: Conventional Surgery;   Procedure: Laser Ablation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • LET-IMPT and Standard Chemotherapy in Treating Patients With Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer
    NCT03690921
    Conditions:   Anal Canal Squamous Cell Carcinoma;   Stage I Anal Cancer AJCC v8;   Stage II Anal Cancer AJCC v8;   Stage IIA Anal Cancer AJCC v8;   Stage IIB Anal Cancer AJCC v8;   Stage III Anal Cancer AJCC v8;   Stage IIIA Anal Cancer AJCC v8;   Stage IIIB Anal Cancer AJCC v8;   Stage IIIC Anal Cancer AJCC v8
    Interventions:   Drug: Cisplatin;   Drug: Fluorouracil;   Radiation: Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy;   Procedure: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • TCR-engineered T Cells in Solid Tumors
    NCT03686124
    Conditions:   Refractory Cancer;   Recurrent Cancer;   Solid Tumor, Adult;   Cancer
    Interventions:   Biological: IMA203 Product;   Device: IMADetect
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting
  • DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis
    NCT03685539
    Conditions:   Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
    Intervention:   Procedure: Dual-Energy Computed Tomography
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
    NCT03683433
    Conditions:   Acute Bilineal Leukemia;   Acute Biphenotypic Leukemia;   Chronic Myelomonocytic Leukemia;   IDH2 Gene Mutation;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Enasidenib Mesylate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma
    NCT03680586
    Condition:   Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
    Intervention:   Radiation: Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Electronic Neurocognitive Tools in Screening for Mental Capability in Patients Undergoing Liver Surgery
    NCT03678441
    Condition:   Liver and Intrahepatic Bile Duct Disorder
    Interventions:   Behavioral: BrainCheck Cognitive Assessment;   Procedure: Cognitive Assessment
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
    NCT03672539
    Conditions:   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Blasts More Than 10 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 10 Percent of Peripheral Blood White Cells;   CD33 Positive;   Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Gemtuzumab Ozogamicin;   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Study of the Fecal Microbiome in Patients With Parkinson's Disease
    NCT03671785
    Condition:   Parkinson Disease
    Interventions:   Drug: PRIM-DJ2727;   Drug: Placebo oral capsule
    Sponsors:   The University of Texas Health Science Center, Houston;   Kelsey Research Foundation
    Recruiting
  • Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
    NCT03661307
    Conditions:   Acute Myeloid Leukemia;   Blasts More Than 10 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 10 Percent of Peripheral Blood White Cells;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   TP53 Gene Deletion;   TP53 Gene Mutation
    Interventions:   Drug: Decitabine;   Drug: Quizartinib;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Survey of Post-Acute Inpatient Rehabilitation Safety Concerns in Participants With Cancer
    NCT03656224
    Condition:   Malignant Neoplasm
    Intervention:   Other: Survey Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
    NCT03654547
    Conditions:   Advanced Solid Tumors;   Triple Negative Breast Cancer
    Intervention:   Drug: TT-00420
    Sponsor:   TransThera Biosciences Co., Ltd
    Recruiting
  • Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
    NCT03637816
    Conditions:   Anorexia;   Lung Non-Small Cell Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Anamorelin Hydrochloride;   Other: Placebo;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • MRx0518 and Pembrolizumab Combination Study
    NCT03637803
    Conditions:   Oncology;   Solid Tumor;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Melanoma;   Bladder Cancer
    Interventions:   Drug: MRx0518;   Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
    Sponsors:   4D pharma plc;   Merck Sharp & Dohme Corp.
    Recruiting
  • MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
    NCT03634267
    Conditions:   Human Papillomavirus-Related Carcinoma;   Human Papillomavirus-Related Cervical Carcinoma;   Stage IB2 Cervical Cancer AJCC v8;   Stage II Cervical Cancer AJCC v8;   Stage II Vaginal Cancer AJCC v8;   Stage IIA Cervical Cancer AJCC v8;   Stage IIA Vaginal Cancer AJCC v8;   Stage IIA1 Cervical Cancer AJCC v8;   Stage IIA2 Cervical Cancer AJCC v8;   Stage IIB Cervical Cancer AJCC v8;   Stage IIB Vaginal Cancer AJCC v8;   Stage III Cervical Cancer AJCC v8;   Stage III Vaginal Cancer AJCC v8;   Stage IIIA Cervical Cancer AJCC v8;   Stage IIIB Cervical Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Vaginal Cancer AJCC v8
    Interventions:   Radiation: Internal Radiation Therapy;   Procedure: Magnetic Resonance Imaging
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules
    NCT03634241
    Conditions:   Lung Non-Small Cell Carcinoma;   Pulmonary Nodule;   Stage I Lung Cancer AJCC v8;   Stage IA1 Lung Cancer AJCC v8;   Stage IA2 Lung Cancer AJCC v8;   Stage IA3 Lung Cancer AJCC v8;   Stage IB Lung Cancer AJCC v8;   Stage II Lung Cancer AJCC v8;   Stage IIA Lung Cancer AJCC v8;   Stage IIB Lung Cancer AJCC v8
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Milademetan Tosylate and Low-Dose Cytarabine in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
    NCT03634228
    Conditions:   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   TP53 wt Allele
    Interventions:   Drug: Cytarabine;   Drug: Milademetan Tosylate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
    NCT03630991
    Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Recurrent Myelodysplastic Syndrome;   Refractory Acute Myeloid Leukemia;   Refractory Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: Edetate Calcium Disodium;   Dietary Supplement: Multivitamin;   Drug: Succimer
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Intraoperative Investigation of a Directional Lead and Local Field Potentials for the Optimization of Stimulation Efficacy
    NCT03630302
    Condition:   Parkinson
    Intervention:   Device: DBS
    Sponsors:   Abbott Medical Devices;   Baylor College of Medicine;   University of Houston
    Recruiting
  • Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
    NCT03629171
    Conditions:   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: Liposome-encapsulated Daunorubicin-Cytarabine;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
    NCT03622775
    Condition:   Recurrent Plasma Cell Myeloma
    Intervention:   Biological: Daratumumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer
    NCT03620201
    Conditions:   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage II Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8
    Intervention:   Drug: Anti-PD-L1/TGFbetaRII Fusion Protein M7824
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Manual Therapy in Treating Fibrosis-Related Late Effect Dysphagia in Head and Neck Cancer Survivors
    NCT03612531
    Conditions:   Cancer Survivor;   Dysphagia;   Fibrosis;   Head and Neck Carcinoma
    Intervention:   Procedure: Manual Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
    NCT03610490
    Conditions:   High Grade Ovarian Serous Adenocarcinoma;   Metastatic Colorectal Adenocarcinoma;   Oligometastasis;   Ovarian Carcinosarcoma;   Pancreatic Ductal Adenocarcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Ovarian Carcinoma;   Refractory Colorectal Carcinoma;   Refractory Ovarian Carcinoma;   Stage IV Colorectal Cancer AJCC v8
    Interventions:   Biological: Autologous Tumor Infiltrating Lymphocytes MDA-TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Fludarabine Phosphate;   Biological: Interleukin-2;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   Bristol-Myers Squibb;   Iovance Biotherapeutics;   National Cancer Institute (NCI)
    Recruiting
  • FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR Extension
    NCT03607825
    Condition:   Subarachnoid Hemorrhage
    Intervention:   Device: Neurapheresis System
    Sponsor:   Minnetronix
    Recruiting
  • Fluorine F 18 Fluorthanatrace PET/CT in Treating Patients With Primary or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    NCT03604315
    Conditions:   Breast Carcinoma;   Fallopian Tube Carcinoma;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Solid Neoplasm
    Interventions:   Procedure: Computed Tomography;   Radiation: Fludeoxyglucose F-18;   Radiation: Fluorine F 18 Fluorthanatrace;   Procedure: Positron Emission Tomography
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
    NCT03603405
    Conditions:   Glioblastoma;   Anaplastic Astrocytoma
    Intervention:   Drug: ADV/HSV-tk (gene therapy)
    Sponsor:   The Methodist Hospital System
    Recruiting
  • Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
    NCT03600155
    Conditions:   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
    NCT03596086
    Conditions:   Glioblastoma Multiforme;   Astrocytoma, Grade III
    Intervention:   Drug: ADV/HSV-tk (gene therapy)
    Sponsors:   David Baskin MD;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting
  • Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
    NCT03586661
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Endometrial Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Progressive Disease;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
    Interventions:   Drug: Copanlisib;   Drug: Niraparib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
    NCT03586609
    Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Cladribine;   Drug: Cytarabine;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2)
    NCT03583710
    Conditions:   ENSAT Stage I Adrenal Cortex Carcinoma;   ENSAT Stage II Adrenal Cortex Carcinoma;   ENSAT Stage III Adrenal Cortex Carcinoma
    Interventions:   Drug: Cisplatin;   Drug: Etoposide;   Drug: Mitotane;   Procedure: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   Amercian Australian Asian Adrenal Alliance (A5);   European Network for the Study of Adrenal Tumors (ENS@T)
    Recruiting
  • Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
    NCT03581487
    Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Biological: Durvalumab;   Drug: Selumetinib;   Biological: Tremelimumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
    NCT03579472
    Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Triple-Negative Breast Carcinoma;   Progesterone Receptor Negative;   Prognostic Stage IV Breast Cancer AJCC v8
    Interventions:   Drug: Anti-PD-L1/TGFbetaRII Fusion Protein M7824;   Drug: Eribulin Mesylate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer
    NCT03579446
    Conditions:   Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Pain
    Interventions:   Drug: Hydrocodone;   Drug: Hydromorphone;   Drug: Hydromorphone Hydrochloride;   Drug: Levorphanol;   Drug: Morphine;   Drug: Morphine Sulfate;   Drug: Oxycodone;   Drug: Oxymorphone;   Drug: Oxymorphone Hydrochloride;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
    NCT03576547
    Conditions:   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Lymphoblastic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   t(9;22)
    Interventions:   Drug: Dexamethasone;   Drug: Ponatinib Hydrochloride;   Biological: Rituximab;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Standard and Delayed FDG PET/CT After Chemoradiation Therapy in Assessing Patients With Metastatic Head and Neck Squamous Cell Cancer
    NCT03575949
    Conditions:   Metastatic Head and Neck Squamous Cell Carcinoma;   Metastatic Malignant Neoplasm in the Spine;   Positive Lymph Node
    Interventions:   Procedure: Computed Tomography;   Other: Fludeoxyglucose F-18;   Procedure: Positron Emission Tomography
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Brain Targets in Patients With Bladder Emptying Difficulties
    NCT03574610
    Conditions:   Neurogenic Bladder;   Multiple Sclerosis;   Voiding Dysfunction
    Intervention:   Device: Transcranial Rotating Permanent Magnet Stimulator (TRPMS)
    Sponsors:   Rose Khavari, M.D.;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
    NCT03573544
    Conditions:   Metastatic Solid Tumors;   Locally Advanced Solid Tumors
    Interventions:   Drug: OBI-888;   Device: Globo H IHC Assay
    Sponsor:   OBI Pharma, Inc
    Recruiting
  • Cemiplimab in Treating Participants With Recurrent Stage III-IV Head and Neck Squamous Cell Cancer Before Surgery
    NCT03565783
    Conditions:   Advanced Head and Neck Squamous Cell Carcinoma;   Recurrent Head and Neck Squamous Cell Carcinoma;   Resectable Head and Neck Squamous Cell Carcinoma;   Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8;   Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
    Intervention:   Biological: Cemiplimab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • The Effects of Plantar Flexion Training in People With Chronic Stroke
    NCT03548090
    Conditions:   Stroke;   Hemiplegic Gait
    Interventions:   Other: Skateboard exercise at an incline angle of 0 degrees and 50% body weight;   Other: Skateboard exercise at an incline angle of 5 degrees and 50% body weight;   Other: Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 75% body weight;   Other: Skateboard exercise at an incline angle determined to be optimal in phase 1 (either 0 or 5 degrees) and 90% body weight;   Other: Control 4-week exercise intervention;   Other: Experimental 4-week exercise intervention;   Other: Over-ground multi-directional gait training;   Other: Home exercise
    Sponsors:   The University of Texas Health Science Center, Houston;   Texas Woman's University
    Recruiting
  • Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
    NCT03531645
    Condition:   Malignant Neoplasms of Female Genital Organs
    Interventions:   Drug: Fulvestrant;   Drug: Abemaciclib
    Sponsors:   M.D. Anderson Cancer Center;   AstraZeneca;   Eli Lilly and Company
    Recruiting
  • Methylphenidate and Physical Activity to Reduce Cancer Related Fatigue Due to Anti PD1 Immunotherapy
    NCT03525873
    Conditions:   Advanced Malignant Neoplasm;   Metastatic Malignant Neoplasm;   Recurrent Malignant Neoplasm
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Methylphenidate;   Other: Physical Activity;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
    NCT03524170
    Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8
    Interventions:   Drug: Anti-PD-L1/TGFbetaRII Fusion Protein M7824;   Radiation: Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study
    NCT03523767
    Condition:   Major Depressive Disorder
    Interventions:   Biological: S.typhi Injection;   Biological: Normal Saline Injection
    Sponsor:   The University of Texas Health Science Center, Houston
    Recruiting
  • Radial-Probe Endobronchial Ultrasound in Detecting Atelectasis in Patients Undergoing Peripheral Bronchoscopy
    NCT03523689
    Conditions:   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Lung Neoplasm
    Interventions:   Procedure: Bronchoscopy;   Procedure: Radial Probe Endobronchial Ultrasound
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Smartphone Mobile Applications in Enhancing Smoking Cessation Treatment in Current Smokers
    NCT03519451
    Condition:   Current Every Day Smoker
    Interventions:   Other: Internet-Based Intervention;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
    NCT03518112
    Conditions:   Philadelphia Chromosome Negative;   Recurrent B Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Biological: Pegfilgrastim;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
    NCT03508570
    Conditions:   Malignant Peritoneal Neoplasm;   Malignant Retroperitoneal Neoplasm;   Peritoneal Carcinomatosis;   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Cervical Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Fallopian Tube Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Primary Peritoneal Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Fallopian Tube Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Primary Peritoneal Cancer AJCC v8
    Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacokinetic Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • REVOLVE or PureGraft Technique in Processing Fat Grafts for Patients Undergoing Breast Reconstruction
    NCT03502512
    Condition:   Mammoplasty Patient
    Interventions:   Other: Questionnaire Administration;   Procedure: Reconstructive Surgery
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
    NCT03485950
    Condition:   Other Infectious Diseases
    Interventions:   Drug: Cefepime;   Drug: Ceftolozane;   Other: Laboratory Biomarker Analysis;   Drug: Meropenem;   Drug: Piperacillin-Tazobactam;   Drug: Tazobactam
    Sponsors:   M.D. Anderson Cancer Center;   Merck Sharp & Dohme Corp.;   National Cancer Institute (NCI)
    Recruiting
  • Mesenchymal Stromal Cells in Living Donor Kidney Transplantation
    NCT03478215
    Conditions:   Renal Transplantation;   Mesenchymal Stem Cells
    Interventions:   Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion;   Other: Normal Saline (Placebo) Infusion
    Sponsors:   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting
  • Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
    NCT03473730
    Conditions:   Bladder Urothelial Carcinoma;   Clear Cell Renal Cell Carcinoma;   Malignant Urinary System Neoplasm;   Metastatic Kidney Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Procedure: Biopsy;   Biological: Daratumumab;   Other: Laboratory Biomarker Analysis;   Procedure: Metastasectomy;   Procedure: Nephrectomy
    Sponsors:   M.D. Anderson Cancer Center;   Janssen Research & Development, LLC;   National Cancer Institute (NCI)
    Recruiting
  • MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)
    NCT03469284
    Conditions:   Malignant Neoplasm;   Oral Pain;   Stomatitis
    Interventions:   Other: Best Practice;   Drug: Methylene Blue
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
    NCT03465774
    Condition:   Malignant Pleural Effusion
    Interventions:   Drug: Doxycycline;   Device: Indwelling Catheter;   Procedure: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Other: Survey Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
    NCT03460769
    Conditions:   Pancreatic Cancer;   Chronic Pancreatitis;   Diabetes Mellitus Type 3c
    Intervention:   Other: Data Management and Monitoring
    Sponsors:   M.D. Anderson Cancer Center;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting
  • Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
    NCT03458676
    Condition:   Brain Lesion
    Interventions:   Procedure: Advanced Magnetic Resonance Imaging Scan;   Procedure: Standard of Care Brain Biopsy and Tumor Removal
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting
  • Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
    NCT03452930
    Conditions:   Glioblastoma;   Gliosarcoma;   MGMT-Unmethylated Glioblastoma;   Unmethylated MGMT Gene Promoter
    Interventions:   Radiation: Radiation Therapy;   Drug: Tinostamustine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Comprehensive Lifestyle Change To Prevent Breast Cancer
    NCT03448003
    Condition:   Premenopausal
    Interventions:   Other: Cancer Prevention;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • TCR-engineered T Cells in Solid Tumors Including NSCLC and HCC Patients
    NCT03441100
    Conditions:   Solid Tumor, Adult;   Cancer;   Hepatocellular Carcinoma;   Hepatocellular Cancer;   Nonsmall Cell Lung Cancer;   Liver Cancer;   Lung Cancer
    Interventions:   Drug: IMA202 Product;   Device: IMA_Detect
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting
  • Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
    NCT03441061
    Conditions:   Acute Lymphoblastic Leukemia;   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   B Acute Lymphoblastic Leukemia;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   Recurrent B Acute Lymphoblastic Leukemia
    Intervention:   Biological: Inotuzumab Ozogamicin
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
    NCT03439085
    Conditions:   Human Papillomavirus-16 Positive;   Human Papillomavirus-18 Positive;   Metastatic Malignant Neoplasm;   Recurrent Anal Canal Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Penile Carcinoma;   Recurrent Vaginal Carcinoma;   Recurrent Vulvar Carcinoma;   Refractory Malignant Neoplasm;   Stage IV Anal Cancer AJCC v8;   Stage IV Cervical Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Vaginal Cancer AJCC v8;   Stage IV Vulvar Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Vaginal Cancer AJCC v8;   Stage IVA Vulvar Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Vaginal Cancer AJCC v8;   Stage IVB Vulvar Cancer AJCC v8
    Interventions:   Biological: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457;   Biological: Durvalumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
    NCT03436563
    Conditions:   Colon Adenocarcinoma;   High-Frequency Microsatellite Instability;   Metastatic Malignant Solid Neoplasm;   Rectal Adenocarcinoma;   Refractory Colorectal Carcinoma;   Stage IV Colon Cancer AJCC v8;   Stage IV Rectal Cancer AJCC v8;   Stage IVA Colon Cancer AJCC v8;   Stage IVA Rectal Cancer AJCC v8;   Stage IVB Colon Cancer AJCC v8;   Stage IVB Rectal Cancer AJCC v8
    Intervention:   Biological: Anti-PD-L1/TGFbetaRII Fusion Protein M7824
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
    NCT03435952
    Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract
    Interventions:   Drug: Pembrolizumab;   Biological: Clostridium Novyi-NT;   Drug: Doxycycline
    Sponsors:   M.D. Anderson Cancer Center;   BioMed Valley Discoveries, Inc;   Merck Sharp & Dohme Corp.
    Recruiting
  • Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
    NCT03430882
    Conditions:   Recurrent Malignant Solid Neoplasm;   Refractory Malignant Solid Neoplasm
    Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Sapanisertib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer
    NCT03429907
    Condition:   Malignant Neoplasm of Breast
    Interventions:   Behavioral: Mind-Body Exercises;   Behavioral: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   Hackett Foundation
    Recruiting
  • Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
    NCT03426969
    Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer
    NCT03422302
    Conditions:   Lung Carcinoma;   Malignant Respiratory Tract Neoplasm;   Metastatic Malignant Neoplasm in the Lung
    Interventions:   Device: Biphasic Positive Airway Pressure;   Procedure: Computed Tomography;   Procedure: Continuous Positive Airway Pressure;   Procedure: Deep Inspiration Breath Hold;   Radiation: Radiation Therapy Treatment Planning and Simulation;   Radiation: Stereotactic Body Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Apalutamide in Treating Participants With Prostate Cancer Before Radical Prostatectomy
    NCT03412396
    Conditions:   Prostate Adenocarcinoma;   PSA Level Ten to Twenty;   Stage IIB Prostate Cancer AJCC v8;   Testosterone Greater Than 200 ng/dL
    Interventions:   Drug: Apalutamide;   Other: Quality-of-Life Assessment;   Procedure: Radical Prostatectomy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Early Detection of Breast Cancer in a Mammography Screening
    NCT03408353
    Condition:   Breast Cancer
    Interventions:   Behavioral: Questionnaire;   Other: Health Measurements
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting
  • Contrast Enhanced Ultrasound With Lumason in Detecting Liver Cancer in Participants With Cirrhosis
    NCT03407001
    Condition:   Cirrhosis
    Interventions:   Procedure: Contrast-Enhanced Ultrasound;   Drug: Sulfur Hexafluoride Lipid Microspheres;   Procedure: Ultrasound
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Venetoclax in Combination With Decitabine in r/r AML
    NCT03404193
    Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Blasts 10-20 Percent of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   High Risk Chronic Myelomonocytic Leukemia;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome;   Recurrent Acute Biphenotypic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Myelomonocytic Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Recurrent Mixed Phenotype Acute Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Chronic Myelomonocytic Leukemia;   Refractory High Risk Myelodysplastic Syndrome;   Refractory Mixed Phenotype Acute Leukemia;   TP53 Gene Deletion;   TP53 Gene Mutation
    Interventions:   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
    NCT03398161
    Conditions:   Localized Skin Lesion;   Mycosis Fungoides
    Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
    NCT03390296
    Conditions:   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Biological: Anti-OX40 Agonist Monoclonal Antibody PF-04518600;   Drug: Avelumab;   Drug: Azacitidine;   Drug: Gemtuzumab Ozogamicin;   Drug: Glasdegib;   Drug: Glasdegib Maleate;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
    NCT03370718
    Conditions:   Metastatic Carcinoma in the Adrenal Cortex;   Stage III Adrenal Cortex Carcinoma AJCC v8;   Stage IV Adrenal Cortex Carcinoma AJCC v8;   Unresectable Adrenal Cortex Carcinoma
    Interventions:   Drug: Cabozantinib;   Other: Pharmacogenomic Study;   Other: Pharmacokinetic Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients
    NCT03360721
    Conditions:   Castration-resistant Prostate Cancer;   Metastatic Castration Resistant Prostate Cancer
    Interventions:   Drug: Abiraterone Acetate 250 MG Oral Tablet [Zytiga];   Drug: Apalutamide;   Drug: Prednisone
    Sponsors:   M.D. Anderson Cancer Center;   Janssen Scientific Affairs, LLC
    Recruiting
  • Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
    NCT03359954
    Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Positive
    Interventions:   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway
    NCT03359811
    Condition:   Peritoneal Cancer
    Interventions:   Drug: Local Anesthetic Solution;   Drug: Bupivacaine HCl;   Drug: Liposomal Bupivacaine
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting
  • Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
    NCT03323658
    Conditions:   Atypical Ductal Breast Hyperplasia;   Atypical Lobular Breast Hyperplasia;   Ductal Breast Carcinoma In Situ;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma In Situ
    Interventions:   Drug: Bexarotene;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
    NCT03319745
    Conditions:   Stage I Bladder Cancer AJCC v8;   Stage II Bladder Cancer AJCC v8;   Stage III Bladder Cancer AJCC v8;   Stage IIIA Bladder Cancer AJCC v8;   Stage IIIB Bladder Cancer AJCC v8
    Intervention:   Biological: Pembrolizumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
    NCT03318900
    Conditions:   COL6A3 Positive;   HLA-A*0201 Positive Cells Present;   PRAME Positive;   Recurrent Ovarian Carcinoma
    Interventions:   Biological: Aldesleukin;   Drug: CD8-Positive T-Lymphocyte;   Drug: Cyclophosphamide;   Procedure: Leukapheresis;   Biological: Utomilumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
    NCT03307616
    Conditions:   Dedifferentiated Liposarcoma;   Recurrent Dedifferentiated Liposarcoma;   Recurrent Undifferentiated Pleomorphic Sarcoma;   Resectable Dedifferentiated Liposarcoma;   Resectable Undifferentiated Pleomorphic Sarcoma;   Undifferentiated Pleomorphic Sarcoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab;   Radiation: Radiation Therapy
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
    NCT03300544
    Conditions:   Rectal Adenocarcinoma;   Stage III Rectal Cancer AJCC v7;   Stage IIIA Rectal Cancer AJCC v7;   Stage IIIB Rectal Cancer AJCC v7;   Stage IIIC Rectal Cancer AJCC v7;   Stage IV Rectal Cancer AJCC v7;   Stage IVA Rectal Cancer AJCC v7;   Stage IVB Rectal Cancer AJCC v7
    Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Oxaliplatin;   Radiation: Radiation Therapy;   Biological: Talimogene Laherparepvec
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • IACS-010759 in Treating Patients With Relapsed or Refractory Lymphoma or Solid Tumors That Are Advanced, Metastatic, or Unresectable
    NCT03291938
    Conditions:   Advanced Malignant Solid Neoplasm;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Malignant Solid Neoplasm;   Pancreatic Ductal Adenocarcinoma;   Progesterone Receptor Negative;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8;   Recurrent Lymphoma;   Refractory Lymphoma;   Stage II Pancreatic Cancer AJCC v8;   Stage IIA Pancreatic Cancer AJCC v8;   Stage IIB Pancreatic Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Triple-Negative Breast Carcinoma;   Unresectable Solid Neoplasm
    Interventions:   Drug: Oxidative Phosphorylation Inhibitor IACS-010759;   Other: Pharmacodynamic Study;   Other: Pharmacokinetic Study
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • RCT of QPS vs General Information Sheet
    NCT03287492
    Conditions:   Advanced Malignant Neoplasm;   Caregiver;   Physician
    Interventions:   Other: Informational Intervention;   Other: Questionnaire Administration
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
    NCT03283917
    Conditions:   Newly Diagnosed Primary Amyloidosis;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
    Interventions:   Biological: Daratumumab;   Drug: Dexamethasone;   Drug: Ixazomib
    Sponsors:   M.D. Anderson Cancer Center;   Janssen Pharmaceuticals;   Takeda Pharmaceutical
    Recruiting
  • Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
    NCT03278782
    Conditions:   Recurrent Anaplastic Large Cell Lymphoma;   Recurrent Angioimmunoblastic T-Cell Lymphoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Mycosis Fungoides;   Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Refractory Angioimmunoblastic T-Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Refractory Mycosis Fungoides;   Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Pembrolizumab;   Drug: Romidepsin
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma
    NCT03274258
    Conditions:   Kidney Medullary Carcinoma;   Loss of INI 1 Protein Expression;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemia
    NCT03265717
    Condition:   Leukemia, Lymphocytic, Chronic, B-Cell
    Intervention:   Biological: INVAC-1
    Sponsors:   Invectys;   M.D. Anderson Cancer Center
    Recruiting
  • Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
    NCT03263572
    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive;   Recurrent Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia;   t(9;22)
    Interventions:   Biological: Blinatumomab;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Ponatinib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Amgen;   Takeda
    Recruiting
  • Olaparib and High-Dose Chemotherapy in Treating Participants With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
    NCT03259503
    Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent T-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Hodgkin Lymphoma;   Refractory T-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Busulfan;   Drug: Gemcitabine;   Drug: Melphalan;   Drug: Olaparib;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacokinetic Study;   Biological: Rituximab;   Drug: Vorinostat
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine)
    NCT03247309
    Conditions:   Solid Tumor;   Cancer;   Head and Neck Squamous Cell Carcinoma;   Non-small Cell Lung Cancer
    Interventions:   Biological: IMA201 Product;   Diagnostic Test: IMA_Detect;   Diagnostic Test: ACT-HLA
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting
  • Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
    NCT03247088
    Conditions:   Allogeneic Hematopoietic Stem Cell Transplant Recipient;   Donor;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine;   Drug: Mycophenolate Mofetil;   Drug: Sorafenib;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Phase Ib of L-NMMA and Pembrolizumab
    NCT03236935
    Conditions:   Non-Small Cell Lung Cancer;   Malignant Melanoma;   Head and Neck Squamous Cell Carcinoma;   Classical Hodgkin Lymphoma;   Urothelial Carcinoma Bladder;   DNA Repair-Deficiency Disorders
    Interventions:   Drug: L-NMMA;   Drug: Pembrolizumab
    Sponsor:   Jorge G. Darcourt
    Recruiting
  • Brain Perfusion & Oxygenation in Parkinson's Disease With NOH
    NCT03229174
    Conditions:   Parkinson Disease;   Neurogenic Orthostatic Hypotension
    Interventions:   Drug: Droxidopa;   Drug: Placebo
    Sponsors:   William Ondo, MD;   Lundbeck LLC
    Recruiting
  • Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
    NCT03224000
    Conditions:   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Oropharyngeal Cancer
    Interventions:   Procedure: Modified Barium Swallow (MBS);   Behavioral: Swallowing Questionnaire;   Behavioral: Symptom Questionnaire;   Procedure: Video-Strobe Procedure;   Procedure: MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning;   Procedure: Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning;   Radiation: Intensity Modulated Radiotherapy (IMRT)
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC